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ABSTRACT  26 
Midstream urine culture (MSU) remains the gold standard diagnostic test for confirming 27 
urinary tract infection (UTI). We previously showed that patients with chronic lower urinary 28 
tract symptoms (LUTS) below the diagnostic cut-off on MSU culture may still harbour 29 
bacterial infection, and that their antibiotic treatment was associated with symptom 30 
resolution. Here, we evaluated the results of the UK’s MSU culture in symptomatic patients 31 
and controls. Next, we compared the bacterial enrichment capabilities of the MSU culture 32 
with a 50 µl uncentrifuged culture, a 30 ml centrifuged sediment culture, and 16S rRNA gene 33 
sequencing. This study was conducted on urine specimens from 33 LUTS patients attending 34 
their first clinical appointment (mean age = 49 years, standard deviation [SD] = 16.5), 30 35 
LUTS patients on treatment (mean age = 47.8 years, SD = 16.8) whose symptoms had 36 
relapsed, and 29 asymptomatic controls (mean age = 40.7 years, SD = 15.7). We showed that 37 
the routine MSU culture, adopting the UK interpretation criteria tailored to acute UTI, failed 38 
to detect a variety of bacterial species, including recognised uropathogens. Moreover, the 39 
diagnostic MSU culture was unable to discriminate between patients and controls. In contrast, 40 
genomic analysis of urine enriched by centrifugation discriminated between the groups, 41 
generating a more accurate understanding of species richness. In conclusion, the UK’s MSU 42 
protocol misses a significant proportion of bacteria, which include recognised uropathogens, 43 
and may be unsuitable for excluding UTI in patients with LUTS. 44 
 45 
 46 
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 48 
 49 
 50 
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INTRODUCTION 70 
An estimated 150-250 million individuals worldwide develop urinary tract infection (UTI) 71 
every year, making it one of the most frequent types of human infections (1, 2). Midstream 72 
urine culture (MSU) is the gold standard test for its diagnosis. Hospital laboratories in the UK 73 
abide by the Standards for Microbiology Investigations (SMI B 41) protocol, issued and 74 
updated by Public Health England (PHE), which generally recommends a threshold of ≥105 75 
colony forming units per millilitre (cfu/ml) to confirm both uncomplicated and complicated 76 
UTI (3); this criterion is also adopted in many other countries, but varies considerably. The 77 
105 cfu/ml threshold originates from a comparison conducted in the late 1950s of 74 pregnant 78 
female patients with clinically determined acute pyelonephritis and 337 asymptomatic 79 
women (4, 5).  80 
Concerns regarding the suitability of this quantitative cut-off for patients with uncomplicated, 81 
acutely dysuric lower UTI were initially raised by Stamm, for which the evidence-based 82 
suggestion for lowering the colony count to 102 cfu/ml was concluded to be the more 83 
appropriate alternative (6, 7). It is now recognised that culture, interpreted using a single 84 
quantitative threshold, may not be appropriate when used to detect different clinical 85 
manifestations of UTI (urethritis, cystitis, and pyelonephritis). This may be further 86 
complicated by a multitude of host and microbial factors (8, 9), making it increasingly likely 87 
that no single threshold is suitable for the detection of UTI in every clinical circumstance 88 
(10).  89 
The current quantitative MSU threshold is problematic for other reasons. First, bacterial 90 
strains are known to vary in virulence (11), meaning that some strains might generate disease 91 
even at lower concentrations. Second, the concentration of bacteria in urine can vary widely 92 
depending on fluid intake before MSU sampling; a dilute specimen might fall below the 93 
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diagnostic cut-off as a result. Third, recognised uropathogens, including Escherichia coli and 94 
Enterococcus faecalis, adhere to host cells and are also known to invade them to form 95 
intracellular colonies (12-14). Thus, urinary supernatant may be a poor substrate for 96 
recovering sequestered organisms. However, it is also known that an innate immune response 97 
to UTI exacerbates the shedding of urothelial cells into urine (15-19).  98 
An additional problem associated with standard MSU interpretation in the UK is the 99 
dismissal of mixed growth cultures by default. Conventionally, ‘mixed growth’ cultures are 100 
assumed to reflect contamination by organisms recognised to colonise the healthy 101 
periurethral, vaginal and perianal regions (5). Although some laboratories electively consider 102 
the growth of up to three organisms each at >105 cfu/ml to suggest polymicrobial infection, or 103 
may proceed with a repeat assessment, many disregard mixed cultures altogether (3). 104 
However, we and others have shown that polymicrobial infection is common in patients with 105 
lower urinary tract symptoms (LUTS) (13, 20-22). In addition, polymicrobial urosepsis has 106 
been reported in patients who demonstrated identical, mixed isolates from blood and urine 107 
specimens (23, 24). Another study reported that E. coli, a predominant uropathogen, 108 
manifested greater invasive properties when isolated from a polymicrobial culture in contrast 109 
to pure growth (25). This finding is supported by recent work showing that E. faecalis can 110 
bolster E. coli by exporting the nutrient L-ornithine (26).  111 
Few studies have analysed the urinary microbial composition by laboratory outcome (i.e. 112 
negative, mixed, positive cultures), and the majority of such work has assessed culture 113 
techniques adopted in US laboratories (6, 27-30). Given the limitations of culture-based 114 
microbial detection (31-33), characterisation of microbial communities in health and disease 115 
is now becoming increasingly dependent on approaches, such as DNA-based identification, 116 
which do not require growth in particular culture conditions (34). Using metagenomics, the 117 
urinary microbiota in patients with neurogenic bladder dysfunction (35), overactive bladder 118 
Page 6 of 47 
 
(36), urgency urinary incontinence (UUI) (28), stress urinary incontinence (37) and 119 
uncomplicated UTI (38) have been described. Some studies have also included comparisons 120 
to asymptomatic individuals (28, 33, 35, 36, 39-41).  121 
Critical microbiological evaluation of the urine culture protocol adopted in the UK is long 122 
overdue. Here, we chose to study MSU culture performance in patients describing LUTS, 123 
including those who fall short of a positive culture and those demonstrating mixed growth, 124 
since these are generally deemed not to have a bona fide infection. This assertion hinges on 125 
standard culture-based diagnosis, and emerging data (13, 28, 42) suggest that such patients 126 
harbour chronic infection. Our aim was to evaluate the MSU culture in symptomatic patients 127 
and asymptomatic controls and assess its performance using both culture and molecular 128 
approaches, with and without specimen enrichment.  129 
 130 
MATERIALS AND METHODS 131 
Subject recruitment and clinical assessment. This study obtained ethical approval from the 132 
East London & the City Research Ethics Committee, London, UK. Adult men and women 133 
aged ≥18 years with LUTS were eligible for study inclusion. Pregnant subjects were not 134 
included in the study. Since urine cultures are relied upon for diagnosis at initial presentation 135 
and during relapse, two separate symptomatic patient groups were recruited and assessed. 136 
Patients attending their first appointment at the Whittington Hospital Lower Urinary Tract 137 
Symptoms (LUTS) Clinic (referred to in this study as “new patients”), who were not on 138 
antibiotic treatment and had not taken antibiotics in the preceding four weeks, were evaluated 139 
by the present clinician and inducted into the first patient group. Patients attending a follow-140 
up consultation with symptomatic recurrence, relapse or no response to initial antimicrobial 141 
treatment (referred to as “relapsed patients”) were identified following clinical assessment to 142 
form the second patient group. Asymptomatic controls aged ≥18 years of either sex, with no 143 
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urological complications and not on antibiotic treatment were recruited from departmental 144 
staff, students and the general population. All patients and controls provided written consent 145 
prior to study inclusion. Figure 1 presents a workflow of all experimental procedures 146 
conducted on each subject. Clinicians overseeing the care of new and relapsed patients were 147 
blinded from all urinalyses results (i.e. urinary dipstick, microscopy and MSU culture test 148 
results). For all downstream analysis, the culture plates were coded with a four-digit study 149 
number and processed separately in large batches. The data for each technique were inputted 150 
separately and comparisons did not take place until all of it had been entered and the code 151 
broken.  152 
Symptoms of urgency urinary incontinence (UUI), voiding dysfunction, pain, and stress 153 
urinary incontinence (SUI) were recorded using “yes/no” response questions in a validated 154 
questionnaire (43). The context-related symptoms were summed within each of the four 155 
symptom groups. Patient and control urine specimens were obtained using the clean-catch 156 
MSU method and anonymised with a four-digit study number. Subjects were carefully 157 
instructed in the collection technique. Each urine specimen was analysed using urinary 158 
dipsticks and an automated Clinitek Status analyser (Siemens Healthcare, Germany) for 159 
leukocyte esterase and nitrites. Microscopic leukocyte counts were determined using a 160 
Neubauer counting chamber, loaded with 10 µl of fresh urine. Each prepared specimen was 161 
examined by microscopy (x200) using an Olympus CX41 light microscope (Olympus, UK).  162 
National routine diagnostic screening. An aliquot of each MSU specimen was submitted to 163 
the Whittington Hospital Microbiology Laboratory, London, UK for routine culture. Urine 164 
specimens were stored at 4°C until they were transported to the processing laboratory. These 165 
samples took approximately 60 minutes to arrive and were cultured either immediately on the 166 
same day, or on the next day following overnight storage at 4°C, which reflected usual 167 
practice. The protocol involved inoculating ChromID CPS (now ChromID CPS Elite) 168 
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chromogenic culture medium (bioMérieux, France) with 1μl of uncentrifuged urine, which 169 
was then placed in an ordinary incubator at 37°C. Microbial colonies were identified using 170 
the manufacturer’s colour criteria. A count of ≥105 cfu/ml for one organism was interpreted 171 
as a significant result. Cultures with a colony count below this threshold were reported as “no 172 
significant growth”. MSU cultures, with more than one organism reported as “mixed growth 173 
of n types of organisms”. 174 
Extended culture-based analysis. Urine samples were stored at 4°C for 0.5-4.0 hours before 175 
transportation to the research laboratory (University College London, UK), where they were 176 
processed immediately. An identical MSU culture was performed on an aliquot of the same 177 
urine specimen. Simultaneous to this culture, 50 µl of uncentrifuged urine was plated on 178 
chromogenic agar. From the remaining aliquots of each specimen, 30 ml was centrifuged at 179 
1400 x g for 10 minutes. The sediment was resuspended in 400 µl of sterilised phosphate 180 
buffer saline (PBS) solution (Life Technologies, UK). Ten-fold serial dilutions were 181 
performed using PBS to reveal the presence of morphologically small-sized colonies, where 182 
the growth of other organisms dominated. All cultures were incubated aerobically at 37°C for 183 
18-24 hours.  184 
Identification of cultured isolates. Microbial isolates were identified using matrix-assisted 185 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) using the 186 
MicroFlex LT mass spectrometer (Bruker Daltonics, USA). In the first instance, the direct 187 
colony plate method was employed for identification and each cultured isolate was inoculated 188 
twice onto the target plate. The target plate was left to air-dry before applying 1µl of matrix 189 
solution (Bruker Daltonics, USA) consisting of alpha-cyano-4-hydroxycinnamic acid 190 
dissolved in 50% acetonitrile and 2.5% trifluoroacetic acid. The air-dried target plate was 191 
inserted into the mass spectrometer and time was given for the high vacuum to be restored. 192 
Using the MALDI Biotyper 3.0 software programme (Bruker Daltonics, USA), the isolate 193 
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identifiers were recorded onto the programme and the Bruker Taxonomy library was selected 194 
for the analysis. In the event of an unsuccessful identification, an ethanol-formic acid 195 
extraction protocol was adopted to assist with microbial cell wall disruption and release of 196 
ribosomal proteins (44). A heavy suspension of the unidentified isolate was made in 300 µl of 197 
sterile distilled water. Following the addition of absolute ethanol (900 µl) microbial 198 
suspension, samples were spun down at 20,000 x g for 2 minutes. The resulting ethanol was 199 
discarded and the centrifugation step was repeated. Residual ethanol was removed and the 200 
resulting pellet was left to air-dry at room temperature for 5 minutes. The deposit was 201 
resuspended in 70% formic acid (20 to 50 µl). An equal volume of acetonitrile was added to 202 
this mixture, followed by centrifugation at 20,000 x g for 2 minutes. The supernatant was 203 
then applied onto a sterilised target plate twice and left to air-dry, before resuming with the 204 
direct approach protocol from the point of adding matrix solution to each dried spot. 205 
16S rRNA gene sequencing of urine. Prior to extraction, urine samples for DNA sequencing 206 
were stored at -80°C. Genomic DNA was extracted from each specimen using an approach 207 
adapted from a previously reported phenol-chloroform-isoamyl alcohol and bead-beating 208 
method (45). Specimens were spun down using a pre-cooled centrifuge at 18,000 x g for 5 209 
minutes at 4°C. Cell pellets were resuspended in extraction buffer (500 µl) consisting of 120 210 
mM potassium phosphate (K2PO4) buffer (pH 8.0) with 5% cetyltrimethylammonium 211 
bromide (CTAB) (Sigma-Aldrich, USA) in 0.7 M NaCl. The specimen tubes were vortexed 212 
and contents transferred into pre-sterilised 2 ml tubes containing zirconia/silica beads (0.1mm 213 
diameter). Phenol-chloroform-isoamyl (PCI) (25:24:1) alcohol (500 µl) (Invitrogen, USA) 214 
was added to each sample and kept on ice. The samples were homogenised using a RiboLyser 215 
(Hybaid, Germany) for 30 seconds at 5.5 m/s and spun down at 18,000 x g for 15 minutes. 216 
Chloroform-isoamyl (CI) alcohol (Invitrogen, USA) was added at a 1:1 ratio to the extracted 217 
layer of DNA supernatant. After centrifugation at 18,000 x g for 2 minutes at 4°C, the DNA 218 
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of each sample was precipitated by adding 30% polyethylene glycol (PEG-8000) (Sigma-219 
Aldrich, USA) at a 2:1 ratio.  220 
PCR was performed to amplify the V5-V7 hypervariable regions of the 16S rRNA gene using 221 
the barcoded primers 785F (5’-GGATTAGATACCCBRGTAGTC-3’) and 1175R (5’-222 
ACGTCRTCCCCDCCTTCCTC-3’) (see Table S1) (Sigma, UK). Each 25 µl sample reaction 223 
contained 0.125 µl Moltaq DNA polymerase (0.025 µM) (Molzym, VH Bio Ltd, UK), 2.5 µl 224 
of Molzym buffer (x 1) (Molzym, VH Bio Ltd., UK), 0.5 mM MgCl2, 0.2 mM dNTPs 225 
(Bioline, UK), 1 µl of forward and reverse primer (0.4 µM) and PCR water (Molzym, VH 226 
Bio Ltd., UK). The PCR reaction stages involved an initial denaturation step at 95°C for 5 227 
minutes and subsequently amplified for 30 cycles at 94°C for 30 seconds (denaturation), 228 
54°C for 40 seconds (annealing), 72°C for 60 seconds (elongation) followed by 72°C for 10 229 
minutes and a final hold of 4°C. All sample reactions were performed in duplex. The DNA 230 
concentrations were determined using the Qubit high-sensitivity DNA assay kit (Life 231 
Technologies, UK) and the Qubit 2.0 fluorometer (Life Technologies, UK). The amplicons 232 
were purified using Agencourt AMPure XP-PCR magnetic particles (Beckman Coulter, 233 
USA) and combined in equimolar ratios using elution buffer (Qiagen, UK) to generate three 234 
pooled DNA libraries (libraries 1, 2 and 3) for pyrosequencing on the MiSeq desktop 235 
sequencer (Illumina Inc., USA), using the v2 reagent kit (Illumina Inc., USA). Since library 3 236 
contained samples with the lowest DNA yields, the purification step was repeated for this 237 
pooled library in an attempt to improve on the final DNA concentration. 238 
Our own customised and commercial mock communities were incorporated into DNA 239 
libraries 1 and 2 to verify the DNA sequencing protocol (see Figure S1).   240 
Statistical analysis. All descriptive and inferential statistics were generated using SPSS 241 
version 25.0 software (IBM, USA). Demographic data, age, gender, 24-hour urinary 242 
Page 11 of 47 
 
frequency, nocturia, validated LUTS scores, log-transformed leukocyte counts were 243 
compared across the groups using non-parametric tests. In all cases, except age, homogeneity 244 
of variance was not shown so Mood’s median test was used instead of the Kruskal-Wallis. 245 
Hospital MSU culture data (with the outcomes: “negative”, “mixed growth” and “positive 246 
culture”) were compared across the study groups using the Chi-squared test or Fisher’s exact 247 
test.  248 
The 16S rRNA data was analysed using QIIME (Quantitative Insights Into Microbial 249 
Ecology, qiime.org version 1.8) (46). The raw reads were demultiplexed and assigned to 250 
samples using barcoded sequences. After demultiplexing, the paired-end data were joined to 251 
obtain a single FASTQ file for each sample. These sequences were then clustered into 252 
Operational Taxonomic Units (OTUs) using an open reference OTU picking strategy. The 253 
OTU clusters were assigned to the Greengenes Reference Database 254 
(http://greengenes.lbl.gov) (47) based on 97% sequence similarity (46). OTUs were then 255 
filtered to remove the chimeric sequences (UCHIME) (48) and taxonomy was assigned using 256 
the Ribosomal Database Project (RDP) Classifier (49). Core diversity analyses based on 257 
study group and sample type were performed.  258 
 259 
RESULTS 260 
Clinical characteristics of the patient cohorts providing samples. As previous work 261 
suggested that the gold standard MSU culture was not an optimal diagnostic tool to detect 262 
infection in LUTS patients, we set out to directly compare it with two alternative culture 263 
techniques. We collected clean-catch MSU specimens from 33 untreated new patients (mean 264 
age: 49 years, standard deviation [SD] = 16.5) and 30 patients experiencing a symptomatic 265 
relapse (mean age: 47.8 years, SD = 16.8). Since urine cultures are relied upon for diagnosis 266 
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at initial presentation and during relapse, these two patient groups were recruited and 267 
assessed separately. For comparison, we also recruited 29 asymptomatic controls (mean age: 268 
40.7 years, SD = 15.7). Table 1 details the clinical characteristics of each study cohort. 269 
Statistically similar age distributions were observed for all three study groups (χ2 = 4.4, df = 270 
2, P = 0.113). The majority of patients were female, which reflected the well-known 271 
demographics of UTI.  272 
Firstly, we inspected the differences between patient and control cohorts. None of the 273 
controls reported any LUTS, thus differing significantly from both patient cohorts studied. A 274 
review of the symptomatic history of new patients (n = 30, duration of symptoms was not 275 
recorded for three patients) revealed 1 patient (3.0%) to experience symptoms for <1 year, 16 276 
patients (48.5%) for 1-4 years, 9 patients (27.3%) for 5-10 years and 4 patients (12.1%) for 277 
≥10 years. The median number of daytime and night-time urinary episodes differed across the 278 
three groups, with pairwise post-hoc comparisons identifying a higher median frequency for 279 
new patients and relapsed patients compared with controls (Table 1). We proceeded to 280 
examine the symptomatic differences between new and relapsed patients. Comparisons of 281 
symptom presentation between patient groups revealed that the number of new patients 282 
reporting UUI and SUI symptoms was significantly higher than that of relapsed patients. The 283 
proportion of new and relapsed patients that reported voiding symptoms and pain symptoms 284 
were statistically similar (Table 1).  285 
In addition to observing the presence and absence of symptoms, we also calculated a 286 
symptom score to determine the magnitude of LUTS within each patient group. The number 287 
of symptoms was summed for each of the four categories to provide a score and compared 288 
across the groups using Mood’s median test. The median symptom scores for UUI, SUI, 289 
voiding and pain symptoms categories differed across the three study groups. Post-hoc 290 
analysis revealed higher median UUI, SUI and voiding scores for new patients than relapsed 291 
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patients. However, both patient cohorts had similar pain scores and total symptom scores 292 
(Table 1). Statistical comparison of the respective frequencies for each assessed LUTS 293 
between new and relapsed patient groups are provided within the supplementary material 294 
(Table S2).  295 
Urinary microscopy and dipstick analysis. We performed urinary leukocyte counts to 296 
determine whether patient urine manifested evidence of infection independent of bacterial 297 
assessment. As shown in Table 2, there was a significant difference in log10 leukocyte counts 298 
among the three study groups (χ2 = 6.2, df = 2, P < 0.05). Post-hoc analysis using 299 
Bonferroni’s correction identified significant differences between controls and new patients, 300 
and between controls and relapsed patients. No significant difference in log10 leukocyte 301 
counts was identified between new patients and relapsed patients.  302 
Analysis of the urinary dipstick results showed 13 (39.4%) new patients, 11 (36.7%) relapsed 303 
patients and 6 (20.7%) controls tested positive for leukocyte esterase with only 1 (3.0%) new 304 
patient testing positive for urinary nitrite. The results were unsurprising, as previous work 305 
suggested that the dipstick is not sensitive enough to diagnose infection (leukocyte esterase = 306 
46-66%, nitrite = 6-18%), particularly in patients with non-acute symptoms of UTI (50-52).  307 
Although LUTS can be driven by non-infectious causes, the association between patient 308 
symptoms and leukocyte recruitment demonstrates urinary tract inflammation. This is critical 309 
if an infective aetiology for LUTS is being considered.  310 
Hospital MSU culture results. Next, we determined the relationship between patient 311 
symptoms and their standard MSU results. Table 2 summarises the data, in which the 312 
majority of new patients, relapsed patients and controls were reported to have a negative 313 
MSU culture. Six (9.5%) symptomatic patients showed a positive culture result as did two 314 
(6.9%) controls. A comparison of the hospital MSU culture outcomes revealed that the MSU 315 
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culture was unable to discriminate between the three study groups (χ2 = 1.7, df = 4, P = 316 
0.787). The hospital reports showed that all four new patients with positive cultures grew E. 317 
coli, whereas Enterococcus (n = 1) and a coliform belonging to the 318 
Klebsiella/Enterobacter/Serratia group (n = 1) were reported for the positive MSU cultures 319 
of relapse patients. Proteus (n = 1) and Streptococcus agalactiae (n = 1) were cultivated from 320 
controls.  321 
Further pairwise statistical comparisons of the number of positive and negative MSU cultures 322 
using the Fisher’s exact test were performed. For this particular analysis, “mixed growth” and 323 
“no significant growth” cultures were under the category of “negative” as both results are 324 
traditionally dismissed as insignificant. This analysis indicated that even with the exclusion 325 
of the relapsed group, the MSU culture was still unable to discriminate between 326 
asymptomatic controls and new patients (χ2 = 0.539, df = 1, P = 0.674). The same analysis for 327 
relapsed patients and controls also showed no significant difference (χ2 = 0.0, df = 1, P = 328 
1.0). Likewise, comparison of new patients and relapsed patients showed no difference (χ2 = 329 
0.539, df = 1, P = 0.674). These results further highlight the inability of the MSU culture to 330 
discriminate between the three study groups. 331 
Since the hospital laboratory did not report the microbial composites of mixed growth and 332 
negative MSU cultures, we inspected the 1 µl loop MSU cultures that were replicated in our 333 
own research laboratories subjecting colonies grown on chromogenic agar to MALDI-TOF 334 
MS analysis for identification. The pooled percentage frequencies of organisms identified 335 
from the polymicrobial MSU cultures of new patients (n = 7), relapsed patients (n = 4) and 336 
controls (n = 5) are shown in Figure S2. No colonies on the research laboratory MSU culture 337 
were observed for 17 (58.6%) controls, 12 (36.4%) new patients, and 13 (43.3%) relapsed 338 
patients. Whilst 19 isolates were grown from 12 asymptomatic control MSU cultures, 39 339 
isolates were identified from 21 new patient cultures and 25 isolates were grown from 17 340 
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relapsed patient cultures. With this replicated diagnostic culture, Enterococcus and 341 
Escherichia were predominantly cultured from new patients and relapsed patients, whereas 342 
Streptococcus and Staphylococcus were most frequently isolated from controls. Within this 343 
sample size, Fisher’s exact test confirmed a significantly higher frequency of Escherichia (χ2 344 
= 5.4, df = 1, P < 0.05) and Enterococcus (χ2 = 8.9, df = 1, P < 0.05) isolated from new 345 
patient cultures than from controls. The relapsing patient group was also observed to produce 346 
a significantly higher number of Enterococcus isolates than the control group (χ2 = 6.4, df = 347 
1, P < 0.05). In summary, the quantitative MSU had no discriminatory diagnostic power, but 348 
the microbial communities isolated in the process showed some differences between patients 349 
and controls. 350 
Comparison of culture techniques. We compared the discriminatory power of the hospital 351 
MSU culture with other methods, specifically plating a larger volume of uncentrifuged urine, 352 
and plating samples enriched by centrifugation. As shown in Figure 2, microbial growth was 353 
categorised as “no growth”, “one isolate” and “≥ two isolates” for comparison. Of note, as the 354 
amount of bacterial input increased (from 1 µl supernatant to 50 µl supernatant to centrifuged 355 
sediment); regardless of patient group, more polymicrobial growths were revealed. Using this 356 
alternative categorisation, the MSU culture replicated within our research laboratory was still 357 
unable to discriminate between the three study groups (χ2 = 4.6, df = 4, P = 0.326). 358 
Additionally, culturing more supernatant (50 µl) or the sediment did not improve 359 
differentiation across the three cohorts (χ2 = 11.7, df = 4, P = 0.02 [no significant differences 360 
identified with post-hoc analysis] and χ2 = 8.4, df = 4, P = 0.078. respectively), likely because 361 
as we and others have reported, healthy bladders also harbour polymicrobial growths. These 362 
results suggest that quantitative microbiology is not an adequate diagnostic tool for patients 363 
experiencing LUTS. 364 
Page 16 of 47 
 
Patient and control urinary bacterial communities. Figures 3 illustrates pairwise study 365 
group comparisons of the genera and respective percentage frequencies identified on the 366 
MSU culture (reproduced in-house), 50 µl urine unspun culture and 30 ml sediment cultures 367 
(See figure S3 for species-level characterisation across study groups). As seen with the MSU 368 
culture results, differences were noted among the various groups on sediment culture. Whilst 369 
15 different genera were grown from symptomatic patient sediment cultures (n = 13 from 370 
new patients, n = 11 from relapsed patients) eight genera were isolated from control sediment 371 
cultures. Seven genera were shared by both patient and control groups, which were 372 
Corynebacterium, Enterococcus, Escherichia, Klebsiella, Proteus, Staphylococcus and 373 
Streptococcus. Organisms that were cultivated from patient samples that were not isolated 374 
from control specimens were Candida, Citrobacter, Enterobacter, Lactobacillus, Leclercia, 375 
Morganella and Pseudomonas. In both symptomatic patient groups, Enterococcus, 376 
Staphylococcus and Escherichia were the most abundant organisms. In asymptomatic 377 
controls, Staphylococcus, Enterococcus and, Streptococcus were most frequently isolated. 378 
However, Staphylococcus (χ2 = 3.7, df = 1, P = 0.064) and Streptococcus (χ2 = 2.4, df = 1, P 379 
= 0.2) were present at statistically similar frequencies in patients. Fisher’s exact test revealed 380 
a significantly higher frequency of Enterococcus isolates cultivated from the new patients 381 
than from asymptomatic controls (χ2 = 6.2, df = 1, P < 0.05). No significant difference was 382 
observed with any other genus between new patients and controls. Comparison of frequencies 383 
between control and relapsed patient groups using Fisher’s exact test revealed a significantly 384 
higher frequency of Staphylococcus (χ2 = 6.9, df = 1, P < 0.05), and Streptococcus (χ2 = 7.0, 385 
df = 1, P < 0.05) in controls than relapsed patients. No significant differences in the number 386 
of genera were identified between new and relapsed patient groups.    387 
We went on to analyse urinary bacteria in unprocessed urine (1 ml uncentrifuged) versus 30 388 
ml of urine enriched by centrifugation in new patient versus control study groups using next-389 
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generation sequencing based on rDNA. The percentage of identified sequencing reads or 390 
reads that passed filter (PF) (Q30 >70%) for loaded DNA libraries 1, 2 and 3 were: (i) 77.9% 391 
(10,122,606 PF reads), (ii) 80.0% (14,910,030 PF reads) and (iii) 68.3% (10,129,563 PF 392 
reads) respectively. Bacterial DNA was detected in the urine samples of 32 (97.0%) of 33 393 
recruited new patients (30 uncentrifuged urine samples and 30 centrifuged samples), 26 394 
(89.7%) of 29 control samples (22 uncentrifuged samples and 23 centrifuged samples). 395 
Samples that yielded low DNA concentrations were salvaged with an extended protocol. 396 
Beyond this, bacterial DNA was undetectable in one new patient and three controls. 397 
Figure 4 presents the relative abundance of the 20 most abundant taxa identified from the 398 
uncentrifuged and centrifuged urine samples of new patients and controls (see supplementary 399 
Table S3 for hierarchical classifications). The 20 most abundant taxa made up 81.0% of new 400 
patient sequences and 79.0% of control sequences. The most abundant taxa of the 401 
uncentrifuged urinary bacterial community of new patients from highest to lowest were 402 
Enterobacteriaceae (32.3%), followed by Lactobacillus (15.5%) and Streptococcus (8.7%) 403 
and Enterococcus (8.0%), whereas the most abundant taxa of the new patient urinary 404 
microbial community represented by centrifuged samples were Enterobacteriaceae (26.9%), 405 
Enterococcus (12.8%), Psychrobacter (9.3%) and Streptococcus (8.3%). The most abundant 406 
taxa identified from uncentrifuged control samples were Streptococcus (21.5%), 407 
Enterobacteriaceae (20.1%), Lactobacillus (11.6%) and Gardnerella (7.5%). In contrast, the 408 
most abundant taxa identified from centrifuged control urine samples were Streptococcus 409 
(15.8%), Staphylococcus (14.8%), Enterobacteriaceae (11.5%) and Lactobacillus (9.2%). 410 
From these data, a decrease in overall abundance of Lactobacillus (15.5% uncentrifuged, 411 
7.8% centrifuged) and an increase in abundance of Enterococcus (8.0% uncentrifuged, 12.8% 412 
centrifuged) were observed with the new patient centrifuged urinary community when 413 
compared with the new patient uncentrifuged community. On the other hand, the control 414 
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centrifuged community showed an increase in overall abundance of Staphylococcus (1.9% 415 
uncentrifuged, 14.8% centrifuged) compared with the control uncentrifuged urinary 416 
community. Centrifugation of samples therefore has a strong influence on species recovery. 417 
Moreover, this approach also highlights differences in microbial composition between 418 
patients and controls (similar to what was seen in our sediment culture data [Figure 3]). 419 
Table 3 presents the richness and diversity measures of new patient and control urinary tract 420 
bacterial communities. Richness was assessed by comparing the mean number of OTUs and 421 
mean Chao1 estimator values using the Welch’s two-sample t test. Diversity was assessed by 422 
comparing the mean Shannon index and mean inverse Simpson’s index using the Welch’s 423 
two-sample t test. Pairwise comparisons indicated no significant difference in the mean 424 
number of observed OTUs and Chao1 estimator between patient and control uncentrifuged 425 
samples, centrifuged samples and both combined. Additionally, no significant difference was 426 
observed in the mean Shannon’s index and inverse Simpson’s index between patients and 427 
control communities.  428 
Overall, our analyses show a clear difference between patients with LUTS and controls, 429 
namely that the Enterobacteriaceae was the most abundant taxa associated with disease, and 430 
Streptococcus, with health. However, it is clear the method of sample processing enriches for 431 
different taxa. Specifically, centrifugation enriched Enterococcus in patient samples, and 432 
Staphylococcus in controls. 433 
Comparison of sediment culture and sequencing approaches. As shown in Figure 5, 434 
colour-coded matrices consisting of all cultured bacterial taxa that were detected by 435 
centrifuged sediment culture and 16S rRNA gene sequencing were generated for new patient 436 
centrifuged samples and control centrifuged urine samples. Among all centrifuged samples 437 
37 (59.7%) of 62 contained bacteria that were detected by both culture and sequencing 438 
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methods. Three (9.1%) patient and four (13.8%) control centrifuged samples were sequence-439 
negative, but culture-positive. Two (6.1%) patient and three (10.3%) centrifuged control 440 
samples were culture-negative, but sequence-positive Enterococcus was the most frequently 441 
identified bacterium from both sediment culture and sequencing methods. These genera were 442 
identified from 22 (66.7%) new patient samples. Staphylococcus was the most frequently 443 
identified bacterium by both methods from control samples. This genus was identified from 444 
11 (37.9%) centrifuged samples. Escherichia demonstrated the most cases (n = 14) in which 445 
it was detected by sediment culture, but remained undetected by sequencing. One new patient 446 
sample (NL5) grew Leclercia on sediment culture, but this particular taxa was not detected 447 
by sequencing. This analysis shows that the sequencing method is vastly superior to culture 448 
techniques for bacterial detection, and that culture methods do not recover a large number of 449 
bacterial species, including recognised uropathogens. 450 
 451 
DISCUSSION  452 
A recent commentary in J Clin Micro emphasised how the diagnostic landscape for UTI is 453 
becoming increasingly challenging in the face of alternatives to standard culture (53). The 454 
primary purpose of this study was to evaluate the routine MSU culture performed in UK 455 
diagnostic laboratories. This evaluation is crucial, since culture is considered the gold 456 
standard diagnostic test for confirming or excluding UTI in symptomatic patients, although 457 
evidence suggests that it may be deficient (6, 7). In the UK, symptom-based empirical 458 
antibiotic treatment for acute UTI is recommended (54). The evidence suggests that the 459 
diagnostic accuracy of acute symptoms in previously asymptomatic subjects outperforms 460 
routine culture-based diagnosis (55). By contrast, relapsing patients with LUTS are not as 461 
straightforward and may demonstrate a distinct microbiota under the influence of prescribed 462 
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antimicrobials. The cohort of relapsing patients was consequently excluded from genomic 463 
analysis to aid in clarifying the differences in urinary microbial communities between first-464 
visit patients with LUTS and health. Despite testing negative on routine MSU, such patients 465 
have been shown to harbour uropathogens when their urine is examined with more sensitive 466 
methods (13, 28, 29, 36, 42). Furthermore, symptomatic resolution has been observed 467 
following antibiotic treatment in this type of patient (56). Therefore, we questioned whether 468 
current routine MSU cultures with a >105 cfu/ml threshold were sensitive enough to detect 469 
UTI in patients presenting with LUTS.  470 
Following a symptomatic assessment of LUTS patients, we scrutinised the microbial 471 
composition of each patient and control MSU culture and compared these to the results 472 
reported by the hospital diagnostic laboratory, as well as to organisms identified using other 473 
alternative culture and molecular methods. Crucially, we found that the routine MSU culture 474 
results reported by the diagnostic laboratory failed to discriminate between patients and 475 
control groups. Fewer than 10% of patients with a clinically suspected UTI had a positive 476 
MSU culture, with only four of 33 new patient cultures producing monomicrobial growth at 477 
105 cfu/ml. In contrast, bacterial DNA sequencing revealed bacteria including recognised 478 
uropathogens in 30 of 32 new patients, including symptomatic patients who were reported to 479 
have a negative MSU culture. In this study, 16S rRNA gene sequencing was not applied as a 480 
diagnostic test, but rather, it was used to determine whether recognised uropathogens were 481 
missed with routine culture techniques, and to characterise symptomatic and healthy urinary 482 
bacterial communities.  483 
Our second key finding was that MSU culture grossly underestimated the amount of 484 
polymicrobial growth in patient urine. For example, 36.4% of new patient urines grew mixed 485 
growths; this number rose to 63.6% when more uncentrifuged urine was plated, and to 84.8% 486 
in the case of centrifuged sediment cultures. Although it is now recognised that even healthy 487 
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urine contains bacteria (41), which certainly complicates the diagnostic landscape, our 488 
enhanced culture and genomic analyses showed a clear difference between the taxa isolated 489 
between patients and controls. Specifically, Enterobacteriaceae was the dominant family in 490 
new patients, whereas Streptococcus was foremost in asymptomatic controls. These findings, 491 
taken together with other reports, suggest that automatically discounting polymicrobial 492 
cultures may dismiss symptomatic patients in need of treatment.  493 
There is of course a formal possibility that the mixed growths reported here could simply be 494 
the result of contamination by skin bacteria during sample collection. In the UK, this 495 
possibility is addressed by the UK Standards for Microbiology Investigations, which 496 
recommends the counting of squamous epithelial cells in the urine as a marker for 497 
contamination. However, their utility for this purpose is complicated by the fact that 498 
exfoliation of urothelial cells as an innate immune response to UTI is a recognised 499 
phenomenon, which is widely used as a surrogate marker of infection in both mice and 500 
humans (14, 21, 57-65). Indeed, using antibodies against uroplakin III, a highly specific 501 
marker for cells originating from the urinary tract, we previously demonstrated that the 502 
majority of epithelial cells shed in the urine of symptomatic patients originate from the 503 
bladder (14). Finally, were the presence of mixed growths merely the result of contamination, 504 
we would not expect their presence to cluster statistically with symptoms as they have done 505 
in this study. 506 
Of note, some UTI-associated organisms were shared at the culture level by symptomatic and 507 
asymptomatic patients: Corynebacterium, Enterococcus, Escherichia, Klebsiella, Proteus, 508 
Staphylococcus and Streptococcus. The presence of “uropathogenic" species in controls could 509 
reflect a lack of the appropriate virulence factor expression (11), or immune differences in the 510 
host (for e.g. (66)). However, similar community profiles in the bladder have been seen by 511 
others (13, 28, 29, 42, 67), which makes it likely that the ability to be pathogenic is highly 512 
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context-dependent, and could therefore be influenced by the presence of other species. Such 513 
pathobiont relationships are common in the microbial world (68) and in the case of UTI, have 514 
been reported in mixed infections with E. coli and Enterococcus (25, 26). Furthermore, 515 
voided urine passes through the urethra as well as the bladder; the microbial ecology of the 516 
urethra is poorly understood in the case of UTI (69-71), and further studies are needed to 517 
understand what role such urethral communities might play.  518 
Further afield, microbial community inhabitants in adjacent niches such as the vagina and 519 
perianal region may also influence what species induce UTI pathophysiology. For example, 520 
recent work by Gilbert et al. showed that transient exposure to the vaginal organism 521 
Gardnerella vaginalis could induce dysbiosis, reactivating dormant E. coli in previously 522 
infected mouse bladders (64). Other interactions could be protective; for example, the vaginal 523 
commensal Lactobacillis crispatus, which is known to make the vagina less hospitable to 524 
certain Gram-negative perianal uropathogens, may decrease the instance of recurrent UTI 525 
(72, 73). Indeed, our results showing that Lactobacillus is a dominant organism among the 526 
control samples, consistent with reports from other groups comparing the urine of patients 527 
with LUTS with asymptomatic controls, supports this notion (28). Further research, including 528 
detailed sequence comparisons, is required to understand the mobility and interspecies effects 529 
of the various microbial inhabitants in the region perianal and urethra region. This could 530 
further our understanding of the significance of polymicrobial communities in UTI.  531 
Of interest, the process of centrifugation had a major effect on which taxa dominated, 532 
enriching Enterococcus in patient samples, and Staphylococcus in controls. This is perhaps 533 
unsurprising, given that uropathogens are known to strongly adhere to and, in some cases, 534 
invade urothelial cells (14). These cells are shed into the urine via an innate immune response 535 
that is yet to be fully characterised (63, 74). Therefore, a significant proportion of bacteria in 536 
such specimens – and perhaps those most relevant for pathophysiology – could be cell-537 
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associated, not planktonic. The MSU culture samples a small amount of urine supernatant 538 
and does not access the cell-rich sediment that settles by gravity. Several reports from the 539 
Brubaker group also recognised the limitations of standard culture and developed the 540 
expanded quantitative urine culture (EQUC) protocol. This involves inoculating 541 
uncentrifuged urine onto a broader selection of culture media for optimal species isolation 542 
(28, 36, 42). The approach demonstrated that the routinely performed standard quantitative 543 
culture missed 67% of recognised uropathogens, with the authors suggesting that the method 544 
be used to supplement the standard culture (42). They did not however analyse centrifuged 545 
sediment with this protocol.  546 
In addition to factors beyond control, such as the volume of fluid intake before urine 547 
sampling, even the use of a broader selection of culture media has its limitations (31). The 548 
cultured urinary community depends on the types of specimens analysed, techniques 549 
employed, nutrient medium used, laboratory conditions (e.g. pH, temperature, O2 550 
concentration), as well as the viability, facultative and fastidious natures of urinary tract 551 
organism. Such factors can distort the species richness of the urinary tract community. 552 
Additionally, bacteria may exist in the viable but not cultivable (VBNC) state, also referred to 553 
as conditionally viable environmental (CVEC) cells, active but not cultivable (ABNC) or 554 
dormant cells (75). Such species are more reliably represented by nucleic acid-based 555 
approaches.   556 
In their studies, Brubaker et al. examined bladder urine specimens (specifically collected by a 557 
transurethral catheter [CSU] or suprapubic aspiration [SPA]) (28, 33, 36, 42). In our study, 558 
we used a clean-catch MSU specimen collection technique for several reasons. The aim of 559 
this study was to evaluate the routine MSU culture technique, which is the primary method in 560 
the clinic for collecting a urine sample for culture. In symptomatic patients, catheterisation is 561 
potentially an invasive, uncomfortable and painful method of collection that has also been 562 
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reported to increase the risk of developing an infection (76). Furthermore, catheterisation may 563 
bypass organisms colonising the urethra, which may represent an early stage UTI or 564 
contribute to the infection. Hooton et al. discussed this as a possible reason for why a lower 565 
threshold is usually applied to CSU cultures and a higher count is considered for MSU 566 
cultures, since it is unclear if the latter collection method has sampled bacteria from the 567 
bladder and/or the urethral region (27). 568 
Female subjects formed the majority of patients and controls, in line with the demographics 569 
of UTI. Given that a previous study found some differences between the microbial ecology in 570 
male and female bladders (77), it would be interesting to further explore the effect of sex on 571 
symptomatic urinary microbiota.  572 
The lack of statistical difference between patient and control uncentrifuged samples was 573 
consistent with other studies (28, 78) and could be attributed to the small study cohort. 574 
However statistical comparison of all patient samples (uncentrifuged and centrifuged) to all 575 
control samples (uncentrifuged and centrifuged) using the non-parametric Kruskal-Wallis test 576 
did confirm a significantly higher median number of OTUs in patients than controls. This 577 
suggests that incorporating centrifuged urine samples may clarify the distinction between 578 
patient and control bacterial community richness. 579 
While region-specific 16S rRNA gene sequencing using the MiSeq platform provided a less 580 
biased representation of the urinary bacterial community, it is important to acknowledge the 581 
limitations of this method. Due to the short-read sequencing approach used, approximately 582 
30% (approximately 500 nucleotides) of the 16S rRNA gene was amplified, which makes 583 
identification at the genus level possible, but reliable taxonomic assignment of reads at the 584 
species level elusive. Our comparison of taxa identified by culture and 16S rRNA gene 585 
sequencing revealed that the sequencing method was more capable of identifying the 586 
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cultivable bacterial taxa from patient and control samples compared with the centrifuged 587 
sediment culture technique. However, the sediment culture method permitted bacterial 588 
identification at the species level, which could not be achieved reliably by 16S rRNA gene 589 
sequencing directly from urine. Of note, Escherichia demonstrated one the highest rates for 590 
detection by culture but was often undetected by DNA sequencing among centrifuged and 591 
uncentrifuged samples. This genus belongs to the Enterobacteriaceae family, which are 592 
reported to be challenging to identify reliably at the genus level due to the high degree of 593 
sequence similarities (79). Given that E. coli is a prominent uropathogen, improvements are 594 
needed. A molecular species-level characterisation could be achieved using the more recently 595 
developed third generation sequencing technologies, including the MinION platform series 596 
(80). The potential to reconstruct more than 90% of the 16S rRNA gene makes species-level 597 
characterisation possible.   598 
This study underlines the potential weaknesses of the MSU culture for diagnosing UTI in 599 
patients affected by LUTS, which should now be assessed further in a larger, multi-centre 600 
study. These patients appear to harbour chronic infection, missed by quantitative cultures and 601 
most effectively demonstrated by non-culture techniques. These methods shed light on the 602 
complexity of the bacterial communities within these patients, whose symptoms and the 603 
urinary white blood cell count may be the best indicators of infection until the disease 604 
landscape is better understood. In the meantime, those responsible for UTI detection, 605 
diagnosis and patient care, including clinicians and microbiologists, may wish to use caution 606 
when interpreting a negative or mixed growth MSU result in symptomatic patients, as well as 607 
reassess reporting and treatment guidelines to arrive at a solution most appropriate for 608 
patients, in a way that also preserves antibiotic stewardship efforts (53). Ultimately, a point-609 
of-care test based on a sound understanding of the relevant microbiomes using emerging 610 
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portable genomic technology would revolutionise the diagnostic landscape for this common 611 
affliction. 612 
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FIGURE LEGENDS 901 
Figure 1. Experimental workflow of the study.  Abbreviations: MALDI-TOF MS = Matrix 902 
assisted laser desorption/ionisation time-of-flight mass spectrometry. 903 
Figure 2. Composition types (no growth, pure and mixed cultures) achieved with three 904 
different techniques (MSU culture (1 µl), unspun culture (50 µl) and sediment culture (30 ml) 905 
across study groups. 906 
Figure 3. Pairwise comparisons of the percentage frequencies of organisms identified from 907 
the urine specimens of new patients (n = 33), relapsed patients (n = 30) and controls (n = 29)   908 
using three different culture techniques: routine midstream urine (MSU) culture, unspun 909 
culture of a 50 µl sample volume and a spun sediment culture of a 30 ml sample volume. 3A: 910 
new patients versus controls, 3B: relapsed patients versus asymptomatic controls and 3C: 911 
new patients versus controls. Data are presented as percentages of the total number of isolates 912 
identified. 913 
Figure 4. Percentage sequence abundances of the 20 most abundant taxa detected in both 914 
new patient and control cohorts when categorised by sample type.    915 
Figure 5. Comparison of genus-level taxa detected by sediment culture and 16S rRNA gene 916 
sequencing for new patient (NL) spun samples (n = 33) and asymptomatic control (AC) spun 917 
samples (n = 29). Interpretation: bacteria identified by culture only (pink), sequencing only 918 
(blue), both (purple) and neither (cream). 919 
 920 
 921 
 922 
 923 
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TABLES 1011 
Table 1. Clinical characteristics of each study group. Abbreviations: CI = confidence 1012 
interval, SD = standard deviation, SUI = stress urinary incontinence, UUI = urgency urinary 1013 
incontinence. Superscripts: a = Kruskal-Wallis test, b = Mood’s median test, c = Chi-squared 1014 
test. $ = statistical comparison between new patient and relapsed patient groups only. 1015 
Table 2. Descriptive measures of in-house (clinic) microscopic leukocyte counts and reported 1016 
routine hospital midstream urine culture results for each study group. Abbreviations: wbc = 1017 
white blood cell. 1018 
Table 3. Richness and diversity measures determined for new patients and controls  1019 
 1020 
 1021 
 1022 
 1023 
 1024 
 1025 
 1026 
 1027 
 1028 
 1029 
 1030 
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Table 1. 1031 
 1032 
 1033 
 1034 
CHARACTERISTIC 
NEW PATIENTS  
(n = 33) 
RELAPSED PATIENTS  
(n = 30) 
CONTROLS  
(n = 29) 
P-VALUE 
Demographics     
Female (%) 32 (97.0) 27 (90.0) 26 (89.7)  
Male (%) 1 (3.0) 3 (10.0) 3 (10.3)  
Mean age in years (SD) 48.7 (16.5) 47.8 (16.5) 40.7 (15.7) 0.113a 
Age range 18-77 24-78 20-76  
Urinary Patterns 
(24 hours) 
Mean SD Median  
(95% CI) 
Mean SD Median  
(95% CI) 
Mean SD Median  
(95% CI ) 
 
Frequency  8.8 5.1 6.5 (5.5-10.5) 8.5 3.7 8.0 (6.5-9.5) 5.9 1.5 5.5 (5.5-6.5) < 0.05b 
Nocturia  1.7 1.7 1.5 (0.5-2.0) 1.6 1.9 1.0 (0.0-2.5) 0.3 0.4 0.0 (0.0-0.5) < 0.05b 
Symptoms$ [Yes/No]  
(% within group) 
    
UUI (%) 25 (75.8) 12 (40.0) 0 (0.0) < 0.05c 
Pain (%) 24 (72.7) 26 (86.7) 0 (0.0) 0.172 c 
Voiding (%) 29 (87.9) 21 (70.0) 0 (0.0) 0.080 c 
SUI (%) 17 (51.5) 2 (6.7) 0 (0.0) < 0.001 c 
Number of symptoms  Mean SD Median  
(95% CI) 
Mean SD Median  
(95% CI) 
Mean SD Median 
(95% CI) 
 
UUI symptoms 3.4 2.9 3.0 (1.0-4.0) 1.4 2.2 0.0 (0.0-2.0) 0.0 0.0 0.0 (0.0-0.0) < 0.001b 
Pain symptoms 3.1 2.7 3.0 (1.0-4.0) 3.6 2.9 3.0 (2.0-4.0) 0.0 0.0 0.0 (0.0-0.0) < 0.001b 
Voiding symptoms 4.1 2.8 4.0 (2.0-6.0) 3.6 2.8 4.0 (2.0-5.0) 0.0 0.0 0.0 (0.0-0.0) < 0.001b 
SUI symptoms 0.7 0.8 1.0 (0.0-1.0) 0.3 1.0 0.0 (0.0-0.0) 0.0 0.0 0.0 (0.0-0.0) < 0.001b 
Total symptom score 11.3 5.9 12.0 (9.0-14.0) 8.9 5.2 9.0 (6.0-11.0) 0.0 0.0 0.0 (0.0-0.0) < 0.001b 
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Table 2. 1035 
 1036 
 1037 
 1038 
 1039 
 1040 
 1041 
 1042 
 1043 
 1044 
 1045 
Footnotes:  1046 
$ = ˂105 organisms/ml, or growth of ≥2 organisms at ˂100 colonies 1047 
* = ˃100 colonies  1048 
 1049 
 1050 
DIAGNOSTIC TEST 
NEW PATIENTS 
(n = 33) 
RELAPSED PATIENTS 
(n = 30) 
CONTROLS 
(n = 29) 
CLINIC MICROSCOPIC LEUKOCYTES  
(log10wbc/µl) 
   
Mean log10 cell count, SD (95% CI) 1.7, 0.9 (0.3-1.0) 0.7, 1.0 (0.4-1.1) 0.2, 0.4 (0.1-0.3) 
Median log10 cell count (95% CI) 0.3 (0.0-0.3) 0.5 (0.0-0.8) 0.0 (0.0-0.8) 
Frequencies (% of group)    
zero wbc/µl 15 (45.5) 12 (40.0) 20 (69.0) 
1-9 wbc/µl 11 (33.3) 11 (36.7) 8 (27.6) 
≥10 wbc/µl 7 (21.2) 7 (23.3) 1 (3.4) 
HOSPITAL MIDSTREAM URINE CULTURE     
No significant growth$ 21 (63.6) 23 (76.7) 22 (75.9) 
Mixed growth* of two organisms 3 (9.1) 2 (6.7) 4 (13.8) 
Mixed growth of three organisms 4 (12.1) 2 (6.7) 1 (3.4) 
>105 cfu/ml of one organism 4 (12.1) 2 (6.7) 2 (6.9) 
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Table 3. 1051 
METRIC NEW PATIENTS CONTROLS 
 Unspun (n = 30) Spun (n = 30) Both (n = 60) Unspun (n = 22) Spun (n = 23) Both (n = 45) 
OTU Numbers       
Mean (SD) 237.5 (122.4) 243.5 (145.1) 247.0 (137.7) 271.8 (271.8) 264.7 (235.2) 276.2 (214.0) 
Median 251.0 224.0 247.5 247.0 217.5 230 
Min-Max 4-510 7-606 4-619 10-639 6-1016 6-1016 
Chao1 estimator       
Mean (SD) 310.2 (147.7) 317.0 (159.7) 333.3 (164.4) 341.6 (205.0) 336.9 (253.0) 362.5 (255.9) 
Median 340.9 283.4 334.2 315.1 295.6 321.1 
Min-Max 7-570.5 7.2-706.0 7-740.6 20.5-780.2 7.5-1085.7 7.5-1193.4 
Shannon’s index       
Mean (SD) 1.6 (0.8) 1.7 (0.9) 1.7 (0.9) 1.8 (0.8) 1.7 (0.8) 1.7 (0.8) 
Median 1.5 1.8 1.7 1.9 1.7 1.8 
Min-Max 0.3-3.3 0.5-3.3 0.3-3.3 0.4-3.2 0.3-3.4 0.3-3.4 
Inverse Simpson’s Index       
Mean (SD) 3.4 (2.8) 4.0 (3.2) 3.7 (3.0) 3.9 (2.6) 3.9 (3.5) 3.9 (3.0) 
Median 2.6 3.0 2.7 3.3 2.5 3.1 
Min-Max 1.1-14.6 1.2-13.2 1.1-14.6 1.1-11.6 1.1-17.0 1.1-17.0 
